September 6, 2014 5:28 PM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
John Schroer of Allianz Global Investors
spoke on CNBC's Fast Money about the biotech stocks he likes.He said that his first pick would be
Biogen Idec (NASDAQ: BIIB), which is a leading company in the multiple sclerosis space. He thinks that the company will have 20 to 25 percent earnings growth over the next three years and it has a valuation of 25 times earnings. The biotech stock sold off on Friday on the news about potential pricing pressure on
Gilead's (NASDAQ: GILD) hepatitis C medicine. Schroer thinks that
Gilead is a great stock, trading at 11 times earnings, with a strong growth potential that could easily trade at $200 billion market capitalization.
Celgene Corporation (NASDAQ: CELG) has also found its place on the list of stocks in the biotech space that John Schroer would buy.
Celgene fell 0.15% on Friday and it closed at $93.79.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.